CYCLE: Granted patent, industrial scale-up, and improved liquidity mark a pivotal growth phase
· Issued by Cyclezyme AB
Major milestones include a granted European patent, successful industrial feasibility study, and new funding for technology scale-up. Financials show stable losses but improved cash flow and strong equity ratio, with sufficient liquidity for the coming year.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
